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Summary The purpose of this study was to compare the efficacy and safety of the
inhaled budesonide, sustained-release theophylline and montelukast, a leukotriene
receptor antagonist, in patients with mild persistent asthma. In this single-center,
randomized, parallel-group study that not designed blindly and placebo-controlled
manner, 74 patients with mild persistent asthma were treated with either inhaled
budesonide 400 mg once daily, oral montelukast 10mg once daily, or sustained-release
theophylline 400mg once daily for 3 months.
In all three treatment groups, improvements were attained in overall asthma
control. Asthma symptom scores and supplemental b2-agonist use were quite the
same in all three treatment groups (P40:05). Although inhaled budesonide group
resulted in significantly greater improvements compared with the other two groups in
the lung functions (Po0:05), the changes in FEV1 and PEF are within the baseline
variability and there was no statistically significant difference among the groups when
analyzed by treatment month (P40:05). Exacerbations of asthma were experienced
by 16% of the patients in the montekulast group, by 12.5% of the patients in the
theophylline group, and by none of the patients in the budesonide group. The adverse
event in each of the three groups was 12%, 16% and 16.7%, respectively.
It is concluded that the most important clinical parameters do not point that one of
the treatments is more effective than others. Treatment with inhaled corticosteroid
is preferred, but sustained-release theophylline and leukotriene antagonists are
alternative controller medications in mild persistent asthma.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
In order to take asthma under control and main-
tain, controller medications with anti-inflammatory
properties are recommended as the primary long-
term control medications in patients with mild
persistent asthma. Because alternative controller
medications, theophylline and leukotrienes, are
less effective than inhaled glucocorticosteroid,
treatment with an inhaled glucocorticosteroid is
preferred in patients with mild persistent asthma
according to the GINA 2002 Report.1 More clinical
experience is necessary for being sure about
alternative controller medications roles in the
treatment of patients with mild persistent asthma.
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Leukotriene modifiers medications prevent the
effects of proinflammatory leukotrienes by either
inhibition of enzymatic production of leukotrienes
or by antagonism of leukotriene receptor binding.2
It is specified that theophylline, a bronchodilator
medicine, has an anti-inflammatory effect which is
due to an unknown mechanism at the low concen-
trations (5–10mg l1).3–6 To date, because few
clinical trials have compared the clinical efficacy
and safety of control therapies, the benefits of
these drugs within an asthma management program
are not very clear. In patients with mild persistent
asthma, studies that compare the efficacy of the
other medications recommended as an alternative
to inhaled corticosteroid treatment should be
done. In addition, evidence is accumulating that
once-daily treatment may be as effective as twice
daily administration, although inhaled corticoster-
oids have traditionally been given twice daily.7,8
For this reason, we designed a study to compare
the efficacy of three different treatment given
once-daily protocols in mild persistent asthma.
Patients and methods
Patients
A total of 74 patients, aged 23–45 years (mean
34.675 years), defined as having mild persistent
asthma according to the criteria of Global Initiative
for Asthma (GINA), Global Strategy for Asthma
Management and Prevention Program Report1 were
enrolled in the study. The forced expiratory volume
in one second (FEV1) at baseline had to be at least
80% of the predicted normal value, with an increase
of at least 15% in FEV1 from the baseline value after
the inhalation of 400 mg of salbutamol. All of the
patients were previously using inhaled budesonide
at a dose of 200 mg a day or equivalent doses of
beclomethasone dipropionate or fluticasone pro-
pionate and short-acting b2-agonist irregularly for
at least 2 months prior to study. Patients were
excluded if they had respiratory tract infection,
smoked cigarettes or had a respiratory disorder
other than asthma disease, had asthma exacerba-
tions within the preceding 2 months, pregnant or
lactating women or with hypersensitivity to sym-
pathomimetic amines and women of childbearing
potential who did not use a reliable contraceptive
method. All of the patients gave their written
informed consent, having been informed about the
details of the study.
This clinical trial was a single-center, rando-
mized, parallel-group study that not designed
blindly and placebo-controlled manner. The study
had a 3-week run-in period, followed by 3 months
of randomized treatment. All patients entering the
run-in period received inhaled budesonide at a dose
of 200 mg twice daily, plus 250 mg of inhaled
terbutaline as needed. After a run-in period of 3
weeks, eligible patients were randomized to each
treatment group in simply random sampling method
according to random numbers table. To these
groups the following three different treatment
combinations were applied:
First group (n ¼ 25): inhaled corticosteroid
(Budesonide 400 mg once daily).
Second group (n ¼ 25): Leukotriene receptor
antagonist (Montelukast 10mg once daily).
Third group (n ¼ 24): Sustained-release theo-
phylline (400mg once daily).
Furthermore, all patients were given short-
acting b2-agonist(terbutaline) inhaler as needed.
Concurrent use of any medications that could
interact with the drugs used in the groups was not
allowed.
Asessments
Demographic characteristics were recorded at the
start of the run-in period and patients were given a
diary card to record symptoms, bronchodilator use
and use of study drug. Day-time and night-time
symptom scores were recorded separately.
The day-time asthma symptom score: 0¼ no
breathing problems at all, activity not restricted;
1¼ breathing problems with little or no discomfort,
and no activity restriction; 2¼ breathing problems
with some discomfort, and limitation of strenuous
activity; 3¼ breathing problems with discomfort
and limitation of routine activity; 4¼ breathing
problems at rest with major discomfort and
limitation in routine activity.
Night-time asthma symptom score: 0¼ no
breathing problems; 1¼ one waking up because of
breathing problems, but no use of rescue medica-
tion; 2¼ one waking up because of breathing
problems, controlled by rescue medication;
3¼more than one waking up because of breathing
problems, controlled by rescue medication;
4¼ difficult sleep because of breathing problems,
despite use of rescue medication.9 PEF and the
forced expiratory volume in 1 s (FEV1) were
measured by spirometry during clinic visits at the
start of drug treatment, and after 1, 2, 3 months of
treatment before administration of study medica-
tions. The spirometer was calibrated before use by
each new patient. The highest PEF value from three
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satisfactory exhalations was recorded. In addition,
during this control period, patients were assessed
with respect to their harmony to the treatment,
adverse events, keeping of daily cards in an orderly
manner and the asthma exacerbations. Patients not
obeying the study protocol and observing asthma
exacerbations were withdrawn from the study.
Asthma exacerbations occurring during this study
were defined as any worsening of asthma symptoms
requiring a change in the patient’s asthma therapy
other than increased use of supplemental terbuta-
line.
This study was conducted in accordance with the
Declaration of Helsinki amended the 52nd WMA
General Assembly (Edinburgh, 2000), and approved
by local ethics committees.
Statistical analysis
Data processing and statistical analysis were
performed using GraphPad InStat (V2.04a). The
primary objective of this study was to compare
the effect of the three treatment regimens for the
entire 3-month treatment period. The primary
efficacy measure was morning PEF. Secondary
efficacy measures included asthma symptom
scores, supplemental terbutaline use, FEV1 and
asthma exacerbations. A sample size of 25 patients
per treatment arm was estimated to provide
greater than 80% power to detect a significant
difference of 12 lmin1 in morning PEF measure-
ments at a significance level of 0.05. For all
endpoints, the average response (change from
baseline or percent change from baseline) was
compared among treatments by using an analysis of
variance (ANOVA) model. Tukey test was used to
assess the groups which create significant differ-
ence. Symptom scores which was not normally
distributed were analyzed using the Freidman test
and Kruskal–Wallis test was used to compare the
differences between the treatment groups. Mann–
Whitney U and Wilcoxon tests by using Bonferroni
correction were performed in order to analyze
which groups have significantly different. All data
were expressed as means7standard deviation.
P-value of less than 0.05 was accepted as statisti-
cally significant.
Results
A total of 74 patients (59 women and 15 men) were
enrolled in the study. The demographic and base-
line disease characteristics are similar in all three
groups (Table 1).
Lung functions
There was no statistically significant difference
among the groups in the initial morning PEF values
(P40:05; Table 1). Although inhaled budesonide
group resulted in significantly greater improve-
ments compared with the other two groups in
morning PEF at the end of the treatment (Po0:001;
Table 2), the change in morning PEF was within the
baseline variability and there was no statistically
significant difference among the groups when
analyzed by treatment month (P40:05; Table 2).
The baseline FEV1 values were similar in all three
groups (P40:05; Table 1). Although a significant
change from baseline at endpoint for FEV1 was seen
in the budesonide group compared with the other
groups (Po0:05), no statistically significant differ-
ence was seen among the groups in the second
and the third month of the treatment (P40:05;
Table 2).
Asthma symptom scores
No statistically significant difference was seen
among the groups in the initial day-time symptom
scores (P40:05; Table 2). A significant decrease in
day-time symptom scores was noted in the all
groups after second month of treatment
(Po0:001). The decrease in symptom score con-
tinued during the third month of the treatment,
but no statistically significant difference was
observed among the groups (P40:05).
Table 1 Demographic and baseline disease characteristics.
Groups (n ¼ 74) Sex (F/M) Age (yr) FEV1(% pred.) PEF morning (lmin
1)
1 Group (n ¼ 25) 20/5 35.975 84.574.1 368.4774.6
2 Group (n ¼ 25) 21/4 34.375 84.875.3 371.2776.8
3 Group (n ¼ 24) 18/6 33.575 86.675.5 378.9772.1
Data are presented as mean7SD. M: male; F: female; FEV1: forced expiratory volume in one second; PEF: peak expiratory flow.
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The initial night-time symptom scores of the
patients were almost at the same level and there
was no statistically significant difference among
the groups (P40:05). While a significant decrease
in the night-time symptom score was seen in the
inhaled budesonide group in the first month of the
treatment (Po0:017), a significant decrease in the
night-time symptom score was seen in the second
month of the treatment in the montelukast and
theophylline groups (Po0:001). Nevertheless, no
statistically significant difference was seen among
the groups in the third month of the treatment
(P40:05).
Supplemental b2-agonist use
There was no statistically significant difference
among the groups in the initial supplemental b2-
agonist use (P40:05; Table 2). A statistically
significant decrease in supplemental b2-agonist
use was seen in all three groups after the first
month of the treatment (Po0:001) and the
significant decrease continued in the second and
third month of the treatment. There was no
statistically significant difference among the three
groups during the treatment period (P40:05).
Adverse events
Adverse events were reported by 12% of patients
receiving inhaled budesonide treatment (dysphonia
in one patient and cough in two patients), 16% of
patients in the montelukast treatment group
(headache in one patient, dyspeptic complaints in
3 patients) and 16.7% of patients in the theophyl-
line treatment group (headache in one patient,
dyspeptic complaints in 3 patients). One patient
was withdrawn from the study due to serious
dyspeptic complaints in the theophylline group.
Asthma exacerbations
Throughout the study, asthma exacerbations were
experienced by 4 patients (16%) and 3 patients
(12.5%) in the montekulast and theophylline treat-
Table 2 Mean (7SD) values at baseline, treatment months 1–3 and change from baseline at endpoint for morning
PEF, FEV1 (% predicted), symptom scores and supplemental terbutaline use.
Baseline 1 month 2 month 3 month Change at
endpoint
Morning PEF
(lmin1) 1 Group
2 Group
3 Group
368.4774.6
371.2776.8
378.9772.1
370.4774.9
374.3777.5
380.3771.6
384.8769.7
376.4772.4
384.0765.5
394.0768.2
381.2773.9
389.0765.6
25.6716.7
9.9715.8
9.5716.1
FEV1( %
predicted ) 1 Group
2 Group
3 Group
84.574.1
84.875.3
86.675.5
82.679.9
82.779.9
85.676.9
86.173.9
84.875.9
85.176.1
89.374.8
85.275.2
87.375.1
4.876.1
0.974.2
0.573.1
Symptom
score
(day-time)
1 Group
2 Group
3 Group
1.970.4
1.870.5
1.770.6
1.670.5
1.770.5
1.870.4
0.970.6
1.170.4
1.170.6
0.570.5
0.670.5
0.570.1
1.570.7
1.370.6
1.270.8
Symptom
score
(night-time)
1 Group
2 Group
3 Group
1.570.5
1.670.4
1.570.5
1.170.4
1.670.6
1.470.6
0.670.6
0.970.6
0.770.6
0.270.4
0.370.5
0.370.5
1.370.6
1.370.5
1.270.7
Mean number
of rescue
inhalations,
puffs/day
1 Group
2 Group
3 Group
0.770.1
0.770.2
0.770.2
0.670.1
0.670.2
0.670.2
0.370.1
0.370.2
0.370.2
0.170.1
0.170.1
0.170.1
0.670.2
0.670.2
0.670.1
Data are presented as mean7SD. PEF denotes peak expiratory flow, and FEV1 (% pred.): forced expiratory volume in 1 s.
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ment groups, respectively. No asthma exacerbation
was seen in the budesonide group.
Discussion
Inhaled corticosteroids have currently taken a
leading role among the controller medications in
current asthma guidelines for the management of
patients with mild persistent asthma.1,10 However,
it is a matter under discussion that the utility and
placement of leukotriene antagonist and sustained-
release theophylline for patients with mild persis-
tent asthma. In this study, the efficacy and safety of
inhaled budesonide, and leukotriene receptor
antagonist and sustained-release theophylline ac-
cepted as alternative controller medications, were
compared for the first time in patients with mild
persistent asthma. Inhaled budesonide group re-
sulted in significantly greater improvements com-
pared with the other two groups in the lung
functions (Po0:05). However, the changes in FEV1
and PEF are within the baseline variability and
there was no statistically significant difference
among the groups when analyzed by treatment
month (P40:05). Dahl et al. showed that theophyl-
line made no significant increase in the FEV1 value
throughout a treatment period of 9 months in
asthmatic patients with an approximately 70% FEV1
values at the beginning, but they found that there
was a significant increase in the inhaled budesonide
groups compared with the pretreatment period.
However, PEF values were unchanged during the
study period in the inhaled budesonide and
theophylline group.11 On the other hand, Busse
et al. stated that there was a significant increase in
morning PEF and FEV1 values of fluticasone propio-
nate compared to montelukast in asthmatic pa-
tients with 50–80% FEV1 values at the beginning.
12
In another study, montelukast had a significant
increase in morning PEF and FEV1 values compared
to placebo in patients with asthma with 40–80%
FEV1 values in the initial state.
13 However, no
statistically significant increase in the FEV1 values
was seen in our montelukast and theophylline
groups compared to initial values. It may be related
with the condition that FEV1 values of all patients
were already over 80% at the beginning.
No statistically significant difference was seen in
the symptom scores and supplemental b2-agonist
use among the three groups at the end of the
treatment (P40:05). GINA include leukotriene
modifiers among the long-term control medications
but the utility and placement of leukotriene
antagonist within the therapeutic management of
mild persistent asthma is unclear.1 In our study,
montelukast treatment resulted in improvements
in asthma symptom scores and decrease in supple-
mental b2-agonist use, but asthma exacerbations
were seen in four patients (16%). Dempsey and et al
showed that leukotriene antagonist and once-daily
treatment with low dose inhaled corticosteroid
produced similar improvements, but only the
inhaled corticosteroid suppressed exhaled nitric
oxide, circulating eosinophils and ECP.14 Low dose
fluticasone propionate was found more effective
than montelukast as first-line therapy for patients
with persistent asthma demonstrated FEV1 of
50–80% of the predicted normal value.12 Further
clinical experience is necessary to establish their
roles in mild persistent asthma.
Recent studies have shown that there is no
difference between using low-dose inhaled corti-
costeroids plus theophylline and using only the
high-dose inhaled corticosteroids.15–17 However, to
our knowledge, there is no comparative data within
mild persistent asthma therapy. No statistically
significant difference was found at the end of the
treatment between the theophylline group and the
other two groups with respect to asthma symptom
scores and supplemental b2-agonist use. However,
asthma exacerbations were seen in 3(12.5%) pa-
tients. Dahl et al. showed that long-term treatment
with high dose of inhaled budesonide was superior
to a low daily budesonide dose and oral theophyl-
line in improvement of lung function, bronchial
reactivity and asthma symptoms.11 Theophylline is
a cheap and easily applied medicine. However, its
side effects and the difficulty of monitoring the
treatment make this medicine less preferred.
In our study, we compared the effect of three
different treatment in steroid-pretreated asth-
matics. For this reason, the impact of our study
to answer the question about the effect of once-
daily therapy with inhaled corticosteroid, theo-
phylline and leukotriene antagonist in patients with
mild persistent asthma is limited. However, our
study may throw light on the studies about the first
line therapy in naive patients with mild persistent
asthma. The lack of placebo group is disadvantage
of our study. Because no placebo group was
examined in our study, it is not clear whether the
clinical treatment effects are different from
placebo.
Although inhaled corticosteroids have usually
been given twice daily, previous studies are
accumulating that once-daily treatment may be
as effective as twice daily administration.7,8,18–20
Inhaled budesonide once-daily administrated re-
sulted in improvements in lung function, symptom
scores and supplemental b2-agonist use and there
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was no asthma exacerbation or serious side effects
in any of our patients. The reversible esterification
of budesonide provides a scientific rationale for the
successful use of inhaled budesonide once-daily
treatment.21 Altman et al have shown that admini-
strated 10, 50, 100 and 200mg montekulast once-
or twice-daily produced no clinical difference in
accordance with the dose or once or twice daily
administration.13 Once-daily treatment may be
expected to offer advantages in terms of simplicity
and convenience to the patient and enhanced
compliance in the long-term control medications.
Haahtela et al. suggest that maintenance therapy
can usually be given at a reduced dose in patients
with mild asthma because discontinuation of
treatment is often accompanied by exacerbation
of the disease.22
While no patients had asthma exacerbation or
side serious effects of the drug in inhaled budeso-
nide group during the study period, 4(16%) patients
had asthma exacerbations in the montelukast group
and 3(12.5%) patients had asthma exacerbations,
and a patient had serious dyspeptic complaints in
the theophylline group. Because an important goal
of asthma therapy is the prevention of worsening
asthma,1,10 asthma exacerbation rate is considered
the most important indicator, although these
agents improve overall control of asthma.
The disadvantage of our study was that the
treatment was not designed blindly and placebo-
controlled manner. Additional studies, particularly
double-blind and double-dummy design, should be
done for being sure about the clinical treatment
effects. In our study, it is not clear whether the
inhalative route itself may have a positive effect on
subjective outcomes and compliance, because no
dummies for the different treatments were used.
Improvements were attained in overall asthma
control in all groups, as a result of treatments
applied. The most important clinical parameters do
not point that one of the treatments is more
effective than others. Symptom scores, supple-
mental b2-agonist use, and the percentage of
adverse effects were quite the same in all three
treatment groups. The only striking difference is
the absence of exacerbations in the budesonide
group in our study.
In conclusion, the results of this study show that
treatment with inhaled corticosteroid is preferred,
but sustained-release theophylline and leukotriene
antagonists are alternative controller medications
in mild persistent asthma. Because multiple
daily administration of any therapy contributes to
poor compliance, once-daily therapy enhanced
compliance in the long-term control medications,
especially asymptomatic or mild symptomatic
patients. We believe that more clinical trials are
necessary for being sure about the roles of
leukotriene antagonists and sustained-release
theophylline in the treatment program of mild
persistent asthma.
Acknowledgements
The authors thanked Dr. Pınar .Ozdemir Geyik,
Hacettepe University Biostatistics Department, for
the statistical analysis.
References
1. National Institutes of Health. Global Initiative for Asthma:
Global Strategy for Asthma Management and Prevention
NHLBI/WHO Workshop Report. National Heart, Lung, and
Blood Institute, 2002.
2. Lipworth BJ. Leukotriene-receptor antagonists. Lancet
1999;353:57–62.
3. Barnes PJ, Pauwels RA. Theophylline in the management of
asthma: time for reappraisal? Eur Respir J 1994;7:579–91.
4. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes
PJ. Immunomodulation by theophylline in asthma. Demon-
stration by withdrawal of therapy. Am J Respir Crit Care Med
1995;151:1907–14.
5. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J.
Anti-inflammatory effects of low-dose oral theophylline in
atopic asthma. Lancet 1994;343:1006–8.
6. Lim S, Tomita K, Carramori G, et al. Low-dose theophylline
reduces eosinophilic inflammation but not exhaled nitric
oxide in mild asthma. Am J Respir Crit Care Med
2001;164:273–6.
7. Herjavecz I, Blomqwist P, Serrano A. Efficacy of once- and
twice-daily administration of budesonide via Turbuhalers as
initial therapy in patients with mild persistent asthma.
Respir Med 1999;93:230–5.
8. Jones AH, Langdon CG, Lee PS, et al. Pulmicorts turbo-
halers once daily as initial prophylactic therapy for asthma.
Respir Med 1994;88:293–9.
9. Molimard M, Bourcereau J, Gros VL, Bourdeix I, Leynadier F,
Duroux P. Comparison between formoterol 12 mg b.i.d. and
on-demand salbutamol in moderate persistent asthma.
Respir Med 2001;95:64–70.
10. National Heart, Lung, and Blood Institute. Expert Panel
Report 2: guidelines for the diagnosis and management of
asthma. Publication No. 97-4051, National Institutes of
Health, Bethesda, MD, 1997.
11. Dahl R, Larsen BB, Venge P. Effect of long-term treatment
with inhaled budesonide or theophylline on lung function,
airway reactivity and asthma symptoms. Respir Med
2002;96:432–8.
12. Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone
propionate compared with montelukast for first-line treat-
ment of persistent asthma: a randomized clinical trial. J
Allergy Clin Immunol 2001;107:461–8.
13. Altman LC, Munk Z, Seltzer J, et al. A placebo-
contolled, dose-ranging study of montelukast, a cysteinyl
leukotriene-receptor antagonist. J Allergy Clin Immunol
1998;102:50–6.
1318 A.S. Yurdakul et al.
14. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy
and anti-inflammatory profile of once-daily therapy with
leukotriene antagonist or low-dose inhaled corticosteroid in
patients with mild persistent asthma. J Allergy Clin Immunol
2002;109:68–74.
15. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ,
Barnes PJ. A comparison of low-dose inhaled budesonide
plus theophylline and high-dose inhaled budesonide for
moderate asthma. N Engl J Med 1997;337:1412–8.
16. Rivington RN, Boulet L-P, Cot !e J, et al. Efficacy of Uniphyls,
salbutamol, and their combination in asthmatic patients on
high-dose inhaled steroids. Am J Respir Crit Care Med
1995;151:325–32.
17. Edwards TB, Dockhorn RJ, Wagner DE, et al. Efficacy of once
daily extended-release theophylline in decreasing the use of
inhaled b2-agonists in stable, mild-to-modorate asthma
patients. Ann Allergy 1995;75:409–16.
18. Chisholm SL, Dekker FW, Neven AK, Petri H.
Once-daily budenosid in mild asthma. Respir Med
1998;92:421–5.
19. Mintz S, Alexander M, Li JH, Mayer PV. Once-daily admin-
istration of budesonide Turbohaler was as effective as twice-
daily treatment in patients with mild to moderate persistent
asthma. J Asthma 2002;39:203–10.
20. Gagnon M, Cote J, Milot J, Turcotte H, Boulet LP.
Comparative safety and efficacy of single twice daily
administration of inhaled beclomethasone in moderate
asthma. Chest 1994;105:1732–7.
21. Brattsand R. Pharmacology of budesonide: factors determin-
ing local efficacy. Pulmicort Turbohalers Once Daily.
International Workshop Report, 1999. p. 15–9.
22. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or
discontinuing inhaled budesonide in patients with mild
asthma. N Engl J Med 1994;331:700–5.
Controller Medications in the treatment of mild persistent asthma 1319
